Principal Research Scientist

Torian Williams Stinnette, M.S.

*** ******** **, ********** ** 19403

Email: ***************@*****.***

Phone: 267-***-****

EDUCATION

Bachelor of Science in Biology University of North Carolina at Chapel Hill 1998 Master of Science in Developmental Biology Thomas Jefferson University 2004 SUMMARY STATEMENT

Innovative, ambitious, and detailed oriented scientist with multiple drug modality experience in oncology, autoimmunity

[inflammation/Immunology], and neuroscience seeking a Principle Scientist or Associate Director role in biological sciences, clinical research, or regulatory. Research tenure include diverse technical skills [cell and molecular biology, biochemistry, ex-vivo and in-vivo studies], pre-clinical assay development [including HTP screening], project management with cross-functional teams, as well as CROs, critical data analysis, competitive intelligence, contract negotiations, presentations, and contribution to IND submissions. TECHNICAL/LABORATORY SKILLS

● Assay Development [target validation, compound activity, HTP cell profiling, etc] o Ex-vivo and in-vitro co-cultures

o Ligand binding

o Immunoassays – ELISA [chemiluminescence, fluorescence, luminescence] o Bioassays – immune cell targeting, antibody-dependent cell mediated cytotoxicity [ADCC] assay

● Functional Assays

o Molecular – western, southern, and northern blots, RT-PCR, RNA isolation, protein extraction and purification, transient and stable cell line generation using plasmid DNA or viral vectors (such as Lentivirus or AAV), and plasmid preparation and upscale

o Cellular – proliferation, cell cycle, degradation, apoptosis [Caspace Marker, Annexin V, TUNEL assay], migration, differentiation, cytokine/chemokine release, toxicity, reactive oxygen species (ROS), HiBiT Assays o Biochemical – kinase signaling using Elisa or protein arrays, G-protein coupled signaling (cAMP), degradation analysis using multi-color flow cytometry, western blots, or immunocytochemistry

● In-vivo Models

o Mouse xenograft studies, arthritic inductions [CIA and AIA models], small biodistribution studies, rodent dosing

[i.p, subQ, i.v. and oral], necropsies, small surgical procedures, cardiac punctures, synovial membrane excision, extraction of active and inactive peritoneal macrophages, removal of spinal cord for synaptosome preparation

● Microscopy/Imaging

o Immunofluorescence (IF/ICC), organ tissue freezing techniques, frozen and paraffin tissue sectioning, immunohistochemistry (IHC)

● Other

o Handing of radioactive material (chromium, gadolinium, 99nTc, and indium), NIH image analysis software, imagePro analysis system, Biomek Liquid Handler, HighRes, Multidrop combi, Echo Liquid dispensing LEADERSHIP AND EXTERNAL INNOVATION

• Identify opportunities to accelerate targets/assets to clinical phases [i.e improving human validation]

• Identify innovative and novel targets as well as emerging technologies using various databases

• Implement strategies to critically evaluate potential assets that are aligned with therapeutic “unmet needs” to support portfolio

• Set goals and metrics that will determine success/POC pre-clinically, as well as a return investment

• Collaboration with external partners (academia and biotech/pharm industries) and proficiency in applying soft skills to establish rapport and develop meaningful relationships with external partners

• Experience and knowledge of the drug development process

• Comfortable under conditions of ambiguity and utilizing disruptive opportunities

• Direct management of 3-4 Interns with individual assigned projects

• Management of CROs for pre-clinical drug discovery RESEARCH EXPERIENCE

Principle Scientist • Proteovant, Inc., King of Prussia, PA • 11/2022 – 10/2023 Therapeutic Area: Oncology, UPS and degraders

Responsibilities: Design, execute, interpret, and troubleshoot pre-clinical in-vitro profiling assays for translational studies and identification of potential biomarkers

• As in individual contributor, support multi-disciplinary teams to identify, develop, and implement methods to support Target ID, biomarkers, patient stratification, and mechanism of action for the development of protein degraders for cancer, immune- oncology, immunology, and other therapeutic areas

• Work in collaboration with chemistry, structural biology, DMPK, bioinformatics, and additional matrix team members to drive programs through all phases of drug discovery and translational sciences

• Lead the design, development, and execution of innovative cell-based assays to support progression of programs through all phases of drug discovery

• Analyze, interpret, summarize, and present research findings at project team meetings, leadership meetings, and external scientific conferences

• Ensure data quality and data integrity

• Lead and contribute to target assessment endeavors

• Mentor junior scientists and associates

Principle Scientist • DeepCure, Boston, MA • 05/2022 – 07/2022 Therapeutic Area: Oncology and Immunology – small molecules Responsibilities: Biology Lead for portfolio projects, Drive early-stage drug discovery programs from target validation through IND

• Work closely and in collaboration with the Assistant Director of Biology and Chemistry to help build and expand the current portfolio.

• Adopt, adapt and deliver on strategy towards internal target development, specifically biological validation that is aligned to maximize the application company’s AI platform.

• Assist in the design and implementation of novel computational and experimental approaches to internal data generation.

• Represent biology on cross-functional and strategic teams, including external collaborations.

• Provide oversight for work conducted by CROs

Senior Principle Scientist • Eli Lilly and Company, Indianapolis, IN • 02/2012 – 04/2022 Therapeutic Area: Neuroscience/Neuroimmunology – small and large molecules Responsibilities: Project Management, Assay development, and Laboratory Bench Work

• Cross-functional collaboration with chemistry, ADME scientist, and other TA departments to reduce redundancy and optimize pre-clinical in-vitro and ex-vivo studies with high impact on early portfolio entry

• Performed competitive intelligence and SWOT analysis

• Offer ideas of novel targets outside the narrow scope of neuroscience by utilizing literature searches, conference presentations, and clinical databases

• Develop flow schemes and timelines for pre-portfolio new targets of interests

• Develop efforts to improve human validation for newer targets in early discovery

• Offer significant scientific and technical contributions to portfolio and exploratory projects, including independent development, design, implementation, and troubleshooting

• Responsible for supervising, mentoring, and training interns and SEED students on cell culture techniques, molecular and biochemical assays, as well as flow cytometry.

Therapeutic Area: Oncology Business Unit

Responsibilities: Project Management and S&E

• Utilized various resources and tools [databases] to identify potential novel targets or platforms that are within the oncology unit focused areas

• Assist with the critical evaluation of new targets or assets from small biotechnology companies or academia

• Make recommendations [monitor, additional experiments needed, financial partnership, licensing of asset or acquisition] based on review of the company’s pre-clinical package, as well as clinical trail protocol, biomarkers, safety profile and efficacy endpoints

• Attend pre-clinical and clinical meetings, as well as Ops meeting to discuss updates on current assets Research Scientist • Endocyte, Inc, West Lafayette, IN • 02/2007 – 02/2014 Therapeutic Area: Immunology/autoimmunity – Folic Acid Drug Conjugates and Small molecules Responsibilities: Assay Development and Laboratory Bench Work

• Designed, implemented, analyzed and troubleshoot various immune-and cell-based and in-vivo studies [AIA and CIA arthritic animal models]

• Independent assay development and optimization, utilizing flow cytometry, biochemical and molecular analytic endpoints

• Cross-functional collaboration with external partners to perform toxicity and biodistribution studies Associate Scientist I • Medimmune, Inc., Gaithersburg, MD • 05/2004 – 08/2006 Therapeutic Area: Oncology – Large molecule

Responsibilities: Laboratory Bench Work

• Support pre-clinical oncology research efforts involving tyrosine kinases

• Engaged and took initiatives to learn new techniques

• Collaborated with other senior scientists and associates to share resources to accelerate asset in pipeline

• Presented monthly presentations on project update to discovery teams in a research forum

• Attended conferences as an invited speaker and poster presenter Lead Cell Biologist • Epix Pharmaceuticals, Inc., Cambridge, MA • 02/2002 – 05/2004 Therapeutic Area: Toxicology and Oncology

Responsibilities: Project Management, Assay Development, Laboratory Bench Work

• Developed and optimized key in-vitro toxicity studies, including kidney cell toxicity and liver microsomal (TIER II assay) for developed diagnostic contrast agents

• Developed an in-vitro acute inflammation model using monocytes/endothelial cell adhesion assay

• Assisted with small pharmacokinetics (biodistribution) studies in mice

• Developed and optimized a binding assay involving tumor vasculature in a Lewis Murine lung metastasis animal model

• Performed collagen extraction and purification procedure in rat myocardium to assist in-vivo team Associate Scientist • GlaxoSmithKline, King of Prussia, PA • 08/2001 – 01/2002 Therapeutic Area: Oncology – small molecules

Responsibilities: Biomarker Validation, Assay Development, Laboratory Bench Work

• Supported pre-clinical in-vitro studies that heavily involved cell biology assays and performing necropsies, immunohistochemistry (IHC), and immunocytochemistry (ICC)

• Developed ex-vivo biomarker for translational studies INVITED SPEAKER

“Target Cancer Therapies” Meeting, Sponsored by CHI. Cambridge, MA. September 2005 Presentation: “Antibody Targeting of EphA4 Tyrosine Kinase Induces Phosphorylation and Inhibits Malignant Behavior in Pancreatic Tumor Cell.”

PUBLICATIONS

Dicker AP, Williams TL, Grant DS. Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol, 2001 Oct; 24 (5): 438-42.

Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel

(taxotere). Int J Cancer. 2003 Mar 10;104(1):121-9 Dicker AP, Williams TL, Iliakis G, Grant DS. Targeting angiogenic processes by combination low-dose paclitaxel and radiation therapy. Am J Clin Oncol. 2003 Jun;26(3):e45-53.

Lu Y, Stinnette TW, Westrick E, Klein PJ, Gehrke MA, Cross VA, Vlahov IR, Low PS, Leamon CP. Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate. Arthritis Res Ther. 2011 Apr 4; 13(2): 1-18. Henne WA, Kularatne SA, Ayala-López W, Doorneweerd DD, Stinnette TW, Lu Y, Low PS. Synthesis and activity of folate conjugated didemnin B for potential treatment of inflammatory diseases. Bioorg Med Chem Lett. 2012 Jan 1;22(1):709-12 Lu Y, Wollak KN, Cross VA, Westrick E, Wheeler LW, Stinnette TW, Vaughn JF, Hahn SJ, Xu LC, Vlahov IR, Leamon CP. Folate receptor-targeted aminopterin therapy is highly effective and specific in experimental models of autoimmune uveitis and autoimmune encephalomyelitis. Clin Immunol. 2014 Jan;150(1):64-77. ABSTRACTS

T. W. Stinnette, and S.P. Arneric. How do biased u-opioid receptor and non-biased agonists differ on receptor desensitization and downstream signaling? Accepted, 44th Annual Meeting, Society for Neuroscience, Washington, D.C. T. W. Stinnette, C. L. A. Ruble, S.P. Arneric. 6TM and 7TM Variants of the µ-Opioid Receptor (MOR) in Human and Mouse Tissues. Accepted, 43rd Annual Meeting, Society for Neuroscience, San Diego, CA. Torian L. Williams, Adam P. Dicker, Diane R. Connor, and Derrick S. Grant. Inhibition of Angiogenesis by Continuous Low Dose Taxanes Causes Growth Delay of Choriocarcinoma (Jeg-3) in Nude Mice. Accepted, 93rd Annual Meeting, American Association of Cancer Research, San Francisco, CA.

Adam P. Dicker, Torian L. Williams, and Derrick Grant. A Potential Anti-Angiogenic Strategy. Accepted, 42nd Annual Meeting, American Society for Therapeutic Radiation and Oncology, Boston, MA Adam P. Dicker, Torian L. Williams, and Derrick S. Grant. Targeting Angiogenic Processes by Combination Low Dose Squalamine and Radiation Therapy. Accepted, 92nd Annual Meeting, American Association of Cancer Research, New Orleans, LA. Torian L. Williams, Derrick Grant, and Adam P. Dicker. Evaluating the Anti-angiogenic Properties of Docetaxel (Taxotere) in Combination with Radiation. Accepted, 92nd Annual Meeting, American Association of Cancer Research, New Orleans, LA. A. P. Dicker, T. Williams, M. Zahachewsky, and D.S. Grant. Targeting Angiogenic Processes by Inhibition of COX-2 with Rofecoxib

(Vioxx) and Ionizing Radiation. Accepted for oral presentation, American Society for Therapeutic Radiology and Oncology, 43rd Annual Meeting.

Adam P. Dicker, Derrick Grant, Torian Williams, Pramila Rani Anne, Roseann Bonanni, Carolyn Sidor, Edward Gubish, and Walter Curran. Phase I Trial results and preclinical studies of recombinant human Angiostatin (rhA) and Radiotherapy. AACR-NCI-EORTC Annual Meeting, Miami FL, submitted for publication. Adam P. Dicker, Torian Williams, and Derrick Grant. Inhibition of angiogenesis using rofecoxib (Vioxx) and Ionizing Radiation. European Cancer Conference – ECCO II, Eisbon Portugal.

Contact this candidate